Your SlideShare is downloading. ×
0
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Eisai (2007-2008) - Pharmaceutical Management Club at Rutgers ...

471

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
471
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
11
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Eisai Medical Research: Site specifically deals with clinical research and drug development
    Eisai Research Institute of Boston: process and research
    Eisai RTP: pharmaceutical production and formulation R&D facility
  • Morphotek, a biopharmaceutical company that discovers and develops monoclonal antibodies for oncology, inflammatory, and infectious diseases.
  • Aricept patent has three years before expiration.
  • Transcript

    • 1. Eisai Inc.Eisai Inc. Ramzi AyyadRamzi Ayyad Nita SilimkhanNita Silimkhan Sean RyanSean Ryan
    • 2. Mission, Vision, ValuesMission, Vision, Values  Human Health Care (HHC) missionHuman Health Care (HHC) mission  Also Florence Nightingale's signatureAlso Florence Nightingale's signature  Innovative solutions for preventive careInnovative solutions for preventive care  Cure and care for health and well being worldwideCure and care for health and well being worldwide  Vision: responsible, focused, efficient, innovativeVision: responsible, focused, efficient, innovative and solution-oriented pharma companyand solution-oriented pharma company..  Values: Integrity, respect, professionalism, quality,Values: Integrity, respect, professionalism, quality, and teamwork.and teamwork.
    • 3. Eisai Corporation: A Global CompanyEisai Corporation: A Global Company  Founded as Nihon Eisai Co. in Japan in 1941.Founded as Nihon Eisai Co. in Japan in 1941.  Current headquarters in Tokyo JapanCurrent headquarters in Tokyo Japan  More than 9,000 employees worldwideMore than 9,000 employees worldwide  40 subsidiaries and 2 Joint Ventures worldwide.40 subsidiaries and 2 Joint Ventures worldwide.  Joint Ventures:Joint Ventures:  Bracco Corporation (Italian Company), P.T. IndonesiaBracco Corporation (Italian Company), P.T. Indonesia..  Wholly Owned Subsidiaries present in 19 countries:Wholly Owned Subsidiaries present in 19 countries:  North America : U.S.A (5 sites)North America : U.S.A (5 sites)  Europe: U.K., Sweden, Germany, France, Italy, Switzerland,Europe: U.K., Sweden, Germany, France, Italy, Switzerland, Spain, NetherlandsSpain, Netherlands  Asia: Japan, Indonesia, Taiwan, China, India, Malaysia,Asia: Japan, Indonesia, Taiwan, China, India, Malaysia, Singapore, Philippines, South Korea, ThailandSingapore, Philippines, South Korea, Thailand
    • 4. Eisai Inc. of North AmericaEisai Inc. of North America  Eisai first established in the U.S. in 1981Eisai first established in the U.S. in 1981  Headquarters in Woodcliff Lake, NJ as of 2007Headquarters in Woodcliff Lake, NJ as of 2007 Chairman and CEO : Hajime ShimizuChairman and CEO : Hajime Shimizu   President and COO : Lonnel CoatsPresident and COO : Lonnel Coats   VP Business Development: Alex ScottVP Business Development: Alex Scott   VP Finance and CFO: Kenneth R (Ken) KlauserVP Finance and CFO: Kenneth R (Ken) Klauser   VP and General Counsel: Douglas B. SnyderVP and General Counsel: Douglas B. Snyder   VP Sales and Marketing: Frank CirielloVP Sales and Marketing: Frank Ciriello    Research Facilities:Research Facilities:  Eisai Medical Research Inc., Ridgefield NJEisai Medical Research Inc., Ridgefield NJ  Eisai Research Institute of Boston, Andover, MaEisai Research Institute of Boston, Andover, Ma  Eisai Inc./ RTP, Research Triangle Park, NCEisai Inc./ RTP, Research Triangle Park, NC  Other:Other:  Eisai Machinery : Pharmaceutical Machinery SalesEisai Machinery : Pharmaceutical Machinery Sales
    • 5. Eisai’s Alliance/Acquisitions History inEisai’s Alliance/Acquisitions History in the U.S.the U.S.  1994 -- agreement with Pfizer Inc to co-promote Aricept®1994 -- agreement with Pfizer Inc to co-promote Aricept®  1997 -- agreement with Janssen Pharmaceuticals Inc. to co-promote1997 -- agreement with Janssen Pharmaceuticals Inc. to co-promote Aciphex®Aciphex®  2002 -- acquires Cerebyx from Warner Lambert company.2002 -- acquires Cerebyx from Warner Lambert company.  2003 -- agreement with Teva Pharmaceuticals to co-promote rasagiline.2003 -- agreement with Teva Pharmaceuticals to co-promote rasagiline.  2004 -- acquires anti-epileptic drug Zonegran® from Elan Corporation2004 -- acquires anti-epileptic drug Zonegran® from Elan Corporation  2006 -- acquires four oncology-related products from Ligand2006 -- acquires four oncology-related products from Ligand Pharmaceuticals.Pharmaceuticals.  2007 –- acquires Morphotek biopharmaceutical company2007 –- acquires Morphotek biopharmaceutical company
    • 6. Eisai Inc.: Inside the numbersEisai Inc.: Inside the numbers Eisai 5 year stock performance on NYSEEisai 5 year stock performance on NYSE Ticker Symbol: ESALYTicker Symbol: ESALY Apr 11Apr 11thth 2008 price: $34.452008 price: $34.45 Traded as ADR on NYSETraded as ADR on NYSE Osaka Securities ExchangeOsaka Securities Exchange Tokyo Stock ExchangeTokyo Stock Exchange
    • 7. Financial Highlight ComparisonFinancial Highlight Comparison Eisai Pfizer Wyeth Sales Revenue* 6.67 billion 48.42 billion 22.4 billion Income* 6.98 million 8.21 billion 4.62 billion Sales Growth* 12.10% 0.10% 10.10% Income Growth 3.50% 82.10% 18.90% Net Profit Margin* 10.50% 17.05% 20.61% R&D expense per Revenue* 13% 16.71%1 14.5%1 Dividend and yield 1.18 (3.42%) 1.17 (6.26%) 1.12(2.49%) Market Cap 9.79 billion 138.32 billion 60.80 billion EPS* 2.45 1.17 3.37 Forward P/E 13.8 8.6 13.1 *Last 12 months 1 FY 2007 Income Statement SOURCE: MSN MoneySOURCE: MSN Money
    • 8. Percent Growth RatePercent Growth Rate Growth Rates % Eisai Industry S&P 500 Sales (Qtr vs year ago qtr) 8.5 39.4 16.2 Net Income (YTD vs YTD) 17.3 61.5 14.6 Net Income (Qtr vs year ago qtr) 3.5 46.2 8.6 Sales (5-Year Annual Avg.) 9.32 36.68 13.88 Net Income (5-Year Annual Avg.) 14.1 45.57 20.41 Dividends (5-Year Annual Avg.) 32.85 1.22 11.89 Source : MSN MoneySource : MSN Money
    • 9. Liquidity Ratio ComparisonsLiquidity Ratio Comparisons Financial Condition Company Industry S&P 500 Debt/Equity Ratio 0.04 0.5 1.4 Current Ratio 2.1 3.4 1.2 Quick Ratio 1.8 3.1 0.9 Interest Coverage NA 360.9 49.3 Leverage Ratio 1.5 1.9 4.6 Book Value/Share 19.9 8.34 21.59 Source : MSN MoneySource : MSN Money
    • 10. Profitability RatiosProfitability Ratios Investment Returns % Company Industry S&P 500 Return On Equity 13.2 7.6 25.5 Return On Assets 9.2 3 8.2 Return On Capital 12.4 5.5 10.9 Return On Equity (5-Year Avg.) 12.5 -0.9 20.8 Return On Assets (5-Year Avg.) 8.6 2.5 7.5 Return On Capital (5-Year Avg.) 11.4 2.9 10 Source : MSN MoneySource : MSN Money
    • 11. Eisai Recent NewsEisai Recent News  Development of Parkinson disease drug, Perampanel (E 2007),Development of Parkinson disease drug, Perampanel (E 2007), was halted after failing late-stage drug trialwas halted after failing late-stage drug trial.. (Bloomberg.com)(Bloomberg.com)  Eisai won a court battle barring Teva pharmaceutical fromEisai won a court battle barring Teva pharmaceutical from selling the Alzheimer drug, Aricept, which accounts for 40% ofselling the Alzheimer drug, Aricept, which accounts for 40% of the company’s revenues .the company’s revenues . (Bloomberg.com)(Bloomberg.com)  Eisia to resume clinical trial studies on E2012, an alzheimer drug.Eisia to resume clinical trial studies on E2012, an alzheimer drug. (pharmalive.com).(pharmalive.com).  FDA approved Aloxi injection for post operative nausea andFDA approved Aloxi injection for post operative nausea and vomitingvomiting (Eisai press release, 3/02/08)(Eisai press release, 3/02/08)
    • 12. Eisai’s PharmaceuticalsEisai’s Pharmaceuticals Two major moneymakersTwo major moneymakers  AriceptAricept  AciphexAciphex Three othersThree others  CerebryxCerebryx  ZonegranZonegran  FragminFragmin
    • 13. AriceptAricept  improves cognition forimproves cognition for Alzheimer’s disease - oralAlzheimer’s disease - oral  Sales from 75 countriesSales from 75 countries (but not England)(but not England)  Best pill on the market,Best pill on the market, but far from a miracle pillbut far from a miracle pill  Off-patent: November 2010Off-patent: November 2010
    • 14. AciphexAciphex  Proton pump inhibitor, forProton pump inhibitor, for GERD (gastroesophagealGERD (gastroesophageal reflux disease) - oralreflux disease) - oral  Co-marketed with PriCaraCo-marketed with PriCara (Ortho-McNeil, part of(Ortho-McNeil, part of J&J) in U.S.; marketed as ParietJ&J) in U.S.; marketed as Pariet outside U.S.outside U.S.  Also approved for treatment of ulcersAlso approved for treatment of ulcers w/antibiotics (2002)w/antibiotics (2002)  Off-patent: May 2013Off-patent: May 2013
    • 15. FragminFragmin  Clot-buster - injectableClot-buster - injectable  Bought U.S. rights from PfizerBought U.S. rights from Pfizer  Stops deep-vein thrombosisStops deep-vein thrombosis (DVT) which can lead to(DVT) which can lead to pulmonary edema (PE)pulmonary edema (PE)  Also approved for anginaAlso approved for angina w/aspirinw/aspirin  Low-molecular-weight heparins – generalLow-molecular-weight heparins – general heparin problems with Chinese suppliersheparin problems with Chinese suppliers
    • 16. Eisai’s Seizure PortfolioEisai’s Seizure Portfolio  Cerebyx – seizure control - injectableCerebyx – seizure control - injectable -Owned by Pfizer, marketed by Eisai via-Owned by Pfizer, marketed by Eisai via hospital-based sales forcehospital-based sales force  Zonegran – seizure medication - oralZonegran – seizure medication - oral -Bought from Elan-Bought from Elan
    • 17. Eisai’s Oncology PortfolioEisai’s Oncology Portfolio  ONTAKONTAK  Targretin (capsulesTargretin (capsules))  Targretin (gel)Targretin (gel)  Panretin (gel)Panretin (gel)
    • 18. Eisai’s Research FocusEisai’s Research Focus  NeurologyNeurology  Gastrointestinal disordersGastrointestinal disorders  CancerCancer  Acute CareAcute Care
    • 19. The Eisai Research PipelineThe Eisai Research Pipeline Phase I CompoundsPhase I Compounds  E5555 – Critical care acute coronaryE5555 – Critical care acute coronary syndromesyndrome  Aciphex – Gastrointestinal disorderAciphex – Gastrointestinal disorder extended release formulationextended release formulation  E7080 – Cancer oral anti-cancer agentE7080 – Cancer oral anti-cancer agent  E7974 – CancerE7974 – Cancer  E7820 - CancerE7820 - Cancer
    • 20. The Eisai Research PipelineThe Eisai Research Pipeline Phase II CompoundsPhase II Compounds  AS-3201 – Diabetic NeuropathyAS-3201 – Diabetic Neuropathy  E7389 – Cancer non small cell lungE7389 – Cancer non small cell lung cancercancer  E2007 – Neurology-migraine preventionE2007 – Neurology-migraine prevention  Aciphex – Gastrointestinal disorder,Aciphex – Gastrointestinal disorder, pediatric usepediatric use  Aciphex - Gastrointestinal disorder,Aciphex - Gastrointestinal disorder, intermittent therapy for symptomaticintermittent therapy for symptomatic gastroesophageal reflux diseasegastroesophageal reflux disease
    • 21. The Eisai Research PipelineThe Eisai Research Pipeline Phase II Compounds (cont.)Phase II Compounds (cont.)  E7389 – Breast cancerE7389 – Breast cancer  E2007 – Neurology-epilepsyE2007 – Neurology-epilepsy  E7389 – Prostate cancerE7389 – Prostate cancer
    • 22. The Eisai Research PipelineThe Eisai Research Pipeline Phase III/Submission to FDAPhase III/Submission to FDA  E5564 – Critical care-severe sepsisE5564 – Critical care-severe sepsis  Rufinamide – epilepsyRufinamide – epilepsy  Aricept – Severe Alzheimer’s diseaseAricept – Severe Alzheimer’s disease

    ×